| Literature DB >> 31440949 |
Eleni Papakokkinou1,2, Hugo Jakobsson3,4, Augustinas Sakinis5, Andreas Muth6, Bo Wängberg6, Olof Ehn3,4, Gudmundur Johannsson3,4, Oskar Ragnarsson3,4.
Abstract
PURPOSE: To study the usefulness of adrenal venous sampling (AVS) in distinguishing unilateral from bilateral cortisol production in patients with ACTH-independent hypercortisolism and bilateral adrenal lesions, or morphologically normal adrenal glands.Entities:
Keywords: ACTH-independent; Adrenal venous sampling; Autonomous cortisol secretion; Cushing’s syndrome; Hypercortisolism
Mesh:
Substances:
Year: 2019 PMID: 31440949 PMCID: PMC6838037 DOI: 10.1007/s12020-019-02038-0
Source DB: PubMed Journal: Endocrine ISSN: 1355-008X Impact factor: 3.633
Clinical, radiological and biochemical characteristics of the study population
| Pat no | Age (year) | Sex | BMI (kg/m2) | Clinical presentation | Hypercortisolism | Main clinical features | Radiological findings | S- cortisol (nmol/L) after ONDST | ACTH (pmol/L) | UFC (times the ULN) | S-cortisol (nmol/L) at midnight | S-cortisol (nmol/L) after LDDST |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 55 | F | 26.0 | Bilateral adrenal incidentaloma | MACS | Muscle weakness Hypertension | Bilateral adenomas: Right 32 × 18 mm | 840 | 1.7 | 0.8 | 340 | 630 | |
| Left 14 × 8 mm | ||||||||||||
| 60 | F | 23.9 | Bilateral adrenal incidentaloma | MACS | Hypertension Type 2 DM Muscle weakness | Bilateral adenomas: Right 28 × 22 mm | 110 | 1.9 | 1.0 | 93 | 100 | |
| Left 15 × 10 mm | ||||||||||||
| 54 | M | 22.4 | Bilateral adrenal incidentaloma | MACS | Hypertension Weight gain Decreased libido Impaired memory | Bilateral adenomas: Right 19 × 14 mm | 190 | 3.2 | 0.8 | 140 | 120 | |
| Left 28 × 25 mm | ||||||||||||
| 61 | F | 33.0 | Bilateral adrenal incidentaloma | MACS | Hypertension Obesity | Multiple adenomas, two in right adrenal and three in left, largest adenomas: Right 32 × 22 mm | 563 | <0.2 | 0.6 | 250 | 420 | |
| Left 19 × 18 mm | ||||||||||||
| 62 | M | 24.1 | Bilateral adrenal incidentaloma | MACS | Hypertension Muscle weakness Impaired memory | Bilateral adenomas: Right 23 × 16 mm | 120 | 3,6 | 0.9 | 120 | 120 | |
| Left 34 × 36 mm | ||||||||||||
| 60 | F | 30.5 | Bilateral adrenal incidentaloma | MACS | Mild Cushingoid features Hypertension Type 2 DM | Bilateral adenomas: Right 23 × 15 mm | 150 | 2.6 | 0.8 | 170 | 120 | |
| Left 10 × 10 mm | ||||||||||||
| 59 | F | 34.6 | Bilateral adrenal incidentaloma | Moderate CS | Cushingoid features Hypertension Type 2 DM Fatigue Depression | Bilateral adenomas: Right 22 × 15 mm | 610 | 1.1 | 1.3 | 420 | 560 | |
| Left 64 × 50 mm | ||||||||||||
| 57 | M | 34.9 | Bilateral adrenal incidentaloma | Moderate CS | Cushingoid features Hypertension Osteoporosis Fatigue Depression | Bilaterally enlarged adrenal glands: Right 50 × 47 mm | 550 | 0.9 | 4.7 | 570 | 250 | |
| Left 41 × 32 mm | ||||||||||||
| 39 | F | 23.6 | CS | Moderate CS | Cushingoid features Depression Amenorrhea Osteoporosis Fatigue | Normal adrenal glands | 677 | 1.3 | 1.6 | 560 | 747 | |
| 11 | F | 40.8 | CS | Severe CS | Cushingoid features Weight gain Decreased growth rate Hypertension | Normal adrenal glands | 830 | 1.7 | 3.9 | 680 | 340 | |
| 51 | F | 30.1 | CS | Severe CS | Cushingoid features Weight gain Hypertension Type 2 DM Fatigue Muscle weakness | Mildly enlarged adrenal glands bilaterally with suspected 9 mm adenoma in the right adrenal gland | 730 | 2.4/4.0/5.7 | 10.2 | 900 | – |
F female, M male, AVS adrenal venous sampling, MACS mild autonomous cortisol secretion, BMI body mass index, CS Cushing’s syndrome, ACTH adrenocorticotropic hormone at 8 a.m. (ref. 2.0–11 pmol/L), UFC 24-h urinary free cortisol, ULN upper limit of the normal range, ONDST 1 mg overnight dexamethasone suppression test, LDDST low-dose dexamethasone suppression test, DM diabetes mellitus type 2
Results from the adrenal venous sampling (AVS), treatment, histopathological findings and outcome
| Patient no | Interpretation of the AVS | Treatment | Pathology | Follow-up months | Treatment response |
|---|---|---|---|---|---|
| 1 | Right-sided hypercortisolism | Right-sided laparoscopic adrenalectomy | Adrenal adenoma | 31 | Postoperative adrenal insufficiency, 13 kg weight reduction, improved blood pressure and significantly increased muscle strength |
| 2 | Bilateral hypercortisolism | Steroidogenesis inibitor | – | 85 | Significantly improved general well-being and insulin sensitivity |
| 3 | Bilateral hypercortisolism | Steroidogenesis inibitor for 4 months, thereafter surveilance | – | 86 | No improvement after 4 months on medical therapy. No progress of symptoms during active surveilance |
| 4 | Bilateral hypercortisolism | Steroidogenesis inibitor | – | 12 | Improved general well-being |
| 5 | Bilateral hypercortisolism | Steroidogenesis inibitor for 4 months, thereafter surveillance | – | 23 | No improvement on medical therapy, rather deterioration with lethargy and malaise |
| 6 | Bilateral hypercortisolism | Steroidogenesis inibitor for 6 months, thereafter surveillance | – | 50 | Improved general well-being on medical treatment, discontinued due to side-effects. During active surveillance, 25 kg weight reduction and resolusion of DM |
| 7 | Left-sided hypercortisolism | Left-sided adrenalectomy | Adrenal adenoma | 51 | Postoperative adrenal insufficiency. Resolution of all CS features, including hypertension, DM and depression |
| 8 | Bilateral hypercortisolism | Bilateral laparoscopic adrenalectomy | PBMAH | 52 | 20 kg weight reduction. Improved blood pressure and general well-being |
| 9 | Bilateral hypercortisolism | Bilateral laparoscopic adrenalectomy | PPNAD | 107 | Resolution of all CS features. Restoration of regular menstruation and improved general well-being |
| 10 | Bilateral hypercortisolism | Bilateral laparoscopic adrenalectomy | PPNAD | 6 | Resolution of all CS features |
| 11 | Bilateral hypercortisolism | TSS | ACTH-positive pituitary adenoma | 27 | Postoperative adrenal insufficiency and resolution of CS features |
Follow-up months from adrenal venous sampling until the last visit or until 31 December 2017
CS Cushing’s syndrome, ACTH adrenocorticotropic hormone, CS Cushing’s syndrome, AVS adrenal venous sampling, DM diabetes mellitus type 2, PBMAH primary bilateral macronodular hyperplasia, PPNAD primary pigmented nodular adrenocortical disease, TSS transsphenoidal surgery
Results from adrenal venous sampling in 11 patients with hypercortisolism
| Peripheral | Vena cava | Left adrenal | Right adrenal | L SI | R SI | R/L gradient | L/R gradient | |
|---|---|---|---|---|---|---|---|---|
| Patient 1 | ||||||||
| Cortisol (nmol/L) | 480 | 480 | 2400 | 6040 | ||||
| Aldosterone (pmol/L) | 54 | 79 | 564 | 539 | 10.4 | 10.0 | 2.6 | |
| Noradrenaline (nmol/L) | – | 0.8 | 22 | 16 | 3.6 | |||
| Adrenaline (nmol/L) | – | 0.2 | 97 | 58 | 4.2 | |||
| DHEA-s (μmol/L) | 1.7 | 2.2 | 2.2 | 3.8 | 1.5 | |||
| Patient 2 | ||||||||
| Cortisol (nmol/L) | 140 | 140 | 520 | 940 | ||||
| Aldosterone (pmol/L) | 52 | 60 | 228 | 307 | 4.4 | 5.9 | 1.3 | |
| Noradrenaline (nmol/L) | – | – | – | – | – | |||
| Adrenaline (nmol/L) | – | – | – | – | – | |||
| DHEA-s (μmol/L) | 0.76 | 0.69 | 0.9 | 1.0 | 1.6 | |||
| Patient 3 | ||||||||
| Cortisol (nmol/L) | 210 | 220 | 1710 | 1520 | ||||
| Aldosterone (pmol/L) | 78 | 90 | 1830 | 2260 | 23.5 | 29.0 | 1.4 | |
| Noradrenaline (nmol/L) | 1.3 | 1.0 | 1.7 | 15 | 10 | |||
| Adrenaline (nmol/L) | 0.1 | 0.1 | 4.2 | 57 | 14 | |||
| DHEA-s (μmol/L) | 0.6 | 0.6 | 0.6 | 0.8 | 1.3 | |||
| Patient 4 | ||||||||
| Cortisol (nmol/L) | 330 | 300 | 1650 | 2670 | ||||
| Aldosterone (pmol/L) | 141 | 208 | 559 | 1790 | 4.0 | 12.7 | 2.0 | |
| Noradrenaline (nmol/L) | – | – | – | – | – | |||
| Adrenaline (nmol/L) | – | – | – | – | – | |||
| DHEA-s (μmol/L) | – | – | – | – | – | |||
| Patient 5 | ||||||||
| Cortisol (nmol/L) | 120 | – | 1320 | 1830 | ||||
| Aldosterone (pmol/L) | <30 | – | 622 | 1960 | 20.7 | 65.3 | 2.3 | |
| Noradrenaline (nmol/L) | 0.5 | 0.9 | 2.4 | 1.8 | 1.8 | |||
| Adrenaline (nmol/L) | 0.3 | 0.1 | 7.0 | 159 | 16 | |||
| DHEA-s (μmol/L) | 1.6 | 1.6 | 1.9 | 1.6 | 1.6 | |||
| Patient 6 | ||||||||
| Cortisol (nmol/L) | 100 | 110 | 790 | 1450 | ||||
| Aldosterone (pmol/L) | 321 | 279 | 31500 | 5540 | 98.1 | 17.3 | 10.4 | |
| Noradrenaline (nmol/L) | 0.5 | 0.9 | 2.4 | 1.8 | 2.5 | |||
| Adrenaline (nmol/L) | <0.02 | <0.02 | 6.8 | 6.3 | 2.0 | |||
| DHEA-s (μmol/L) | 0.6 | 0.6 | 0.9 | 0.9 | 1.8 | |||
| Patient 7 | ||||||||
| Cortisol (nmol/L) | 540 | 570 | 1620 | 980 | ||||
| Aldosterone (pmol/L) | 57 | 96 | 318 | 1340 | 5.6 | 23.5 | 7.1 | |
| Noradrenaline (nmol/L) | 1.9 | 2.2 | 1.1 | 8.4 | 12.5 | |||
| Adrenaline (nmol/L) | 0.3 | <0.16 | 0.2 | 40 | 330 | |||
| DHEA-s (μmol/L) | 7 | 7 | 7.7 | 7.4 | 1.6 | |||
| Patient 8 | ||||||||
| Cortisol (nmol/L) | 390 | 390 | 1000 | 1530 | ||||
| Aldosterone (pmol/L) | 46 | 50 | 268 | 375 | 5.8 | 8.1 | 1.1 | |
| Noradrenaline (nmol/L) | 1.5 | 1.6 | 3.8 | 2.2 | 2.6 | |||
| Adrenaline (nmol/L) | 0.2 | <0.16 | 18 | 13 | 2.1 | |||
| DHEA-s (μmol/L) | 8.4 | 8.1 | 8.6 | 9.3 | 1.0 | |||
| Patient 9 | ||||||||
| Cortisol (nmol/L) | 510 | 490 | 8200 | 16,300 | ||||
| Aldosterone (pmol/L) | <30 | <30 | 585 | 1410 | 19.5 | 47.0 | 1.2 | |
| Noradrenaline (nmol/L) | 0.6 | 0.4 | 5.7 | 4.4 | 2.6 | |||
| Adrenaline (nmol/L) | <0.02 | <0.02 | 29 | 22 | 2.6 | |||
| DHEA-s (μmol/L) | 3.1 | 2.9 | 4.7 | 6.1 | 1.5 | |||
| Patient 10 | ||||||||
| Cortisol (nmol/L) | 210 | 230 | 5030 | 3930 | ||||
| Aldosterone (pmol/L) | 1220 | 302 | 245 | 186 | * | * | 1.0 | |
| Noradrenaline (nmol/L) | 1.1 | 0.4 | 3.2 | 3.6 | 1.5 | |||
| Adrenaline (nmol/L) | 0.3 | <0.16 | 26 | 55 | 2.7 | |||
| DHEA-s (μmol/L) | 0.13 | 0.12 | 0.2 | 0.2 | 1.3 | |||
| Patient 11 | ||||||||
| Cortisol (nmol/L) | 280 | 260 | 6240 | 12300 | ||||
| Aldosterone (pmol/L) | 230 | 254 | 3870 | 16000 | 16.8 | 69.6 | 2.1 | |
| Noradrenaline (nmol/L) | 0.3 | <0.18 | 2.2 | 2.6 | 1.7 | |||
| Adrenaline (nmol/L) | <0.16 | <0.16 | 12 | 13 | 1.8 | |||
| DHEA-s (μmol/L) | 0.9 | 0.8 | 2.1 | 3.0 | 1.4 | |||
DHEA-s dehydroepiandrosterone-sulfate, L left, R right, SI selectivity index
*Not calculated due to laboratory error of the peripheral sample
Fig. 1Patient with mild autonomous cortisol secretion (MACS) and bilateral adrenal lesions (right lesion 32 × 18 mm and left lesion 14 × 8 mm; Subject 1). AVS showed right-sided cortisol overproduction and right-sided adrenalectomy was performed. Postoperatively the patient developed transient adrenal insufficiency
Fig. 2Patient with overt CS and bilateral adrenal lesions (right lesion 22 × 15 mm and left lesion 64 × 50 mm; Subject 7). AVS showed left-sided cortisol production and the patient underwent left-sided adrenalectomy. Postoperatively the patient developed adrenal deficiency. After 51 months of follow-up the patient has remained in remission
Fig. 3Patient with CS and bilateral lesions (right lesion 50 × 47 mm and left lesion 41 × 32 mm; Subject 8). AVS showed bilateral cortisol production, and bilateral adrenalectomy was performed. The histopathological diagnosis was PBMAH